On heels of pos­i­tive COPD read­out, Verona to pro­vide new pub­lic of­fer­ing

Af­ter Verona Phar­ma’s COPD drug can­di­date proved to be ef­fec­tive in clin­i­cal tri­als and sent in­vestors scur­ry­ing to get in on the ac­tion, the com­pa­ny is now look­ing at im­prov­ing its po­si­tion on the Nas­daq.

The UK biotech kept de­tails close to the vest, but not­ed in a re­lease on Tues­day that the pub­lic of­fer­ing will con­sist of 10 mil­lion Amer­i­can de­posi­tary shares, each rep­re­sent­ing eight or­di­nary shares of Verona Phar­ma at a nom­i­nal val­ue of ap­prox­i­mate­ly six cents per share.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER